Founded in 2016
Engitix is developing a portfolio of programmes in fibrosis and solid tumours using its pioneering human extracellular matrix (ECM) drug discovery platform. The use of more physiologically relevant human in vitro models is transforming their ability to identify new targets, to develop more advanced treatments and to enable a more accurate prediction of the efficacy of therapeutic candidates.
Engitix was founded in 2016 to commercialise cutting-edge research at UCL’s Institute for Liver and Digestive Health. The company is headquartered in White City Place, London, UK.